3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
106
Neoplasms
14
Neoplasm Metastasis
14
Carcinoma, Non-Small-Cell Lung
4
Advanced Breast Cancer
4
Hereditary Sensory and Autonomic Neuropathies
3
Recurrence
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Multiple Endocrine Neoplasia Type 1
2
Endometrial Neoplasms
2
Breast Neoplasms, Male
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Solid Malignancies
1
Recurrent Uterine Corpus Carcinoma
1
Neoplasms by Site
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Locally Advanced (Inoperable) or Metastatic Breast Cancer
1
Lethal Congenital Contracture Syndrome 2
1
Hyperglycemia
1
Hormone Receptor Positive HER-2 Negative Breast Cancer
1
Hormone Receptor Positive Breast Cancer
1
HER2-positive Breast Cancer
1
Female Breast Carcinoma
1
Exanthema
1
Interventions
Oxaliplatin
53
Cisplatin
52
Fluorouracil
50
Capecitabine
48
pembrolizumab
39
Leucovorin
31
Docetaxel
26
Trastuzumab
23
Paclitaxel
20
Irinotecan
20
Ramucirumab
13
Bevacizumab
12
Cetuximab
9
Radiotherapy
8
Surgical Procedures, Operative
7
S 1 (combination)
7
Nivolumab
7
Epirubicin
7
Carboplatin
6
olaparib
5
Platinum
5
Everolimus
5
Sunitinib
4
Mitomycin
4
trastuzumab deruxtecan
3
lenvatinib
3
epacadostat
3
bemarituzumab
3
apatinib
3
Saline Solution
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Stomach Neoplasms
×
Fulvestrant
×
Clear all
NCT03620643
2025-10-30
ROLo
Royal Marsden NHS Foundation Trust
Phase 2
Completed
33 enrolled
13 charts